Treatment of Patients With Myelofibrosis and Uncontrolled Polycythemia Vera
EHA Learning Center. Delivered by Novartis . Aug 23, 2017; 193789
Topic: Section 2: Clinical hematology myeloid malignancies
Delivered by Novartis
 Delivered by Novartis
Login now to access Regular content available to all registered users.

Access to EHA Members only content is an EHA membership benefit.
Click here to join EHA or renew your membership here.

Learning Objectives
Discussion Forum (0)
Rate & Comment (0)
- To determine if patients with early myelofibrosis would benefit from treatment
- To understand the management options for patients with cytopenias on JAK-inhibitor treatment
- To discuss which patients with MF are usually considered for allogeneic stem cell transplant
- To be able to identify uncontrolled polycythemia vera (PV) and discuss which drugs are appropriate options for secondline cytoreduction"
Code of conduct/disclaimer available in General Terms & Conditions